Iron Oxide Nanoparticles: Physicochemical Characteristics and Historical Developments to Commercialization for Potential Technological Applications
Source abstract
Abstract
Iron oxide nanoparticles (IONPs) have gained increasing attention in various biomedical and industrial sectors due to their physicochemical and magnetic properties. In the biomedical field, IONPs are being developed for enzyme/protein immobilization, magnetofection, cell labeling, DNA detection, and tissue engineering. However, in some established areas, such as magnetic resonance imaging (MRI), magnetic drug targeting (MDT), magnetic fluid hyperthermia (MFH), immunomagnetic separation (IMS), and magnetic particle imaging (MPI), IONPs have crossed from the research bench, received clinical approval, and have been commercialized. Additionally, in industrial sectors IONP-based fluids (ferrofluids) have been marketed in electronic and mechanical devices for some time. This review explores the historical evolution of IONPs to their current state in biomedical and industrial applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Characterization and Applications of Magnetic Nanoparticles · Microfluidic and Bio-sensing Technologies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Fundamental Sciences, Massey University, Private Bag 11 222, Palmerston North 4410, New Zealand
Department of Chemistry, Faculty of Women, Ain Shams University, Heliopolis 11757, Cairo, Egypt
Funding
New Zealand Government
References (100+)
Show source-provided references
1. 10.1103/PhysRev.54.109210.1103/PhysRev.54.1092 ↗
2. 10.1016/j.ijpharm.2015.10.05810.1016/j.ijpharm.2015.10.058 ↗
3. 10.1016/j.addr.2010.05.00610.1016/j.addr.2010.05.006 ↗
4. 10.1039/C5CS00541H10.1039/C5CS00541H ↗
5. 10.1088/0022-3727/36/13/20110.1088/0022-3727/36/13/201 ↗
6. 10.1039/C4NR03482A10.1039/C4NR03482A ↗
7. 10.1016/0304-8853(90)90058-X10.1016/0304-8853(90)90058-X ↗
8. 10.1016/S1369-7021(11)70163-810.1016/S1369-7021(11)70163-8 ↗
9. 10.1021/acs.molpharmaceut.6b0083910.1021/acs.molpharmaceut.6b00839 ↗
10. 10.1016/j.msec.2014.09.02310.1016/j.msec.2014.09.023 ↗
11. 10.1016/j.carbpol.2015.04.02210.1016/j.carbpol.2015.04.022 ↗
12. 10.1098/rsfs.2016.004810.1098/rsfs.2016.0048 ↗
13. 10.3390/chemosensors801001710.3390/chemosensors8010017 ↗
14. 10.1021/acsomega.0c0164110.1021/acsomega.0c01641 ↗
15. 10.1002/adtp.20200006110.1002/adtp.202000061 ↗
16. 10.1021/acs.jpclett.5b0061010.1021/acs.jpclett.5b00610 ↗
17. 10.7150/thno.400610.7150/thno.4006 ↗
18. 10.1586/erd.10.9410.1586/erd.10.94 ↗
19. 10.1039/C9CS00174C10.1039/C9CS00174C ↗
20. 10.1142/S179398441000006710.1142/S1793984410000067 ↗
21. 10.1016/j.rpor.2013.09.01110.1016/j.rpor.2013.09.011 ↗
22. 10.1371/journal.pone.015689910.1371/journal.pone.0156899 ↗
23. 10.1517/17425247.2014.92450110.1517/17425247.2014.924501 ↗
24. 10.4155/fmc.09.16410.4155/fmc.09.164 ↗
25. 10.1088/1361-6528/ab424110.1088/1361-6528/ab4241 ↗
26. 10.1021/cn100100e10.1021/cn100100e ↗
27. 10.1007/s13205-018-1286-z10.1007/s13205-018-1286-z ↗
28. 10.1016/j.mattod.2019.06.00310.1016/j.mattod.2019.06.003 ↗
29. 10.1088/1468-6996/16/2/02350110.1088/1468-6996/16/2/023501 ↗
30. 10.1002/adtp.20200006110.1002/adtp.202000061 ↗
31. Lopez-Diaz, L.; Torres, L. Transition from ferromagnetism to superparamagnetism in uniaxial nanoparticles. The role on non-uniformities in the magnetization, In2002 IEEE International Magnetics Conference (INTERMAG), Amsterdam, Netherlands, 28 April-2 May 2002; Amsterdam, Netherlands, 2002; p DD3.10.1109/INTMAG.2002.1001015 ↗
32. 10.1007/s12648-014-0487-510.1007/s12648-014-0487-5 ↗
33. 10.1039/C4RA06902A10.1039/C4RA06902A ↗
34. 10.3390/ijms14112126610.3390/ijms141121266 ↗
35. 10.1080/21691401.2019.170985510.1080/21691401.2019.1709855 ↗
36. 10.1155/2012/61409410.1155/2012/614094 ↗
37. Wang S. · Am. J. Cancer Res. · 2018 · 8 · 1933
38. 10.1148/radiol.228302087210.1148/radiol.2283020872 ↗
39. 10.1038/s41597-020-0392-z10.1038/s41597-020-0392-z ↗
40. 10.1002/ajh.2424010.1002/ajh.24240 ↗
41. 10.3109/17435390.2010.50951910.3109/17435390.2010.509519 ↗
42. 10.1590/S0103-9733200500040001810.1590/S0103-97332005000400018 ↗
43. Charles S. W. · 1980 · 2 · 50910.1016/S1574-9304(05)80109-9 ↗
44. 10.1016/0261-3069(87)90139-710.1016/0261-3069(87)90139-7 ↗
45. 10.1007/s11671-008-9174-910.1007/s11671-008-9174-9 ↗
46. Stephen, P. S. Low viscosity magnetic fluid obtained by the colloidal suspension of magnetic particles. U.S. Patent 3,215,572, 1965.
47. Rosensweig R. E. · 1985
48. 10.1007/s12541-018-0060-910.1007/s12541-018-0060-9 ↗
49. 10.1146/annurev.fl.19.010187.00225310.1146/annurev.fl.19.010187.002253 ↗
50. Raj K. · Indian J. Eng. Mater. Sci. · 2004 · 11 · 241
51. FerroTec. https://ferrofluid.ferrotec.com/ (accessed 2021-11-04).
52. De Roos A. · 1988 · 4110.1007/978-94-009-3279-1_5 ↗
53. 10.1039/C7TC05854C10.1039/C7TC05854C ↗
54. 10.1002/jmri.188004050810.1002/jmri.1880040508 ↗
55. 10.2214/AJR.14.1273310.2214/AJR.14.12733 ↗
56. 10.1039/C6NR01877G10.1039/C6NR01877G ↗
57. 10.1021/ja800736h10.1021/ja800736h ↗
58. 10.1021/ja026501x10.1021/ja026501x ↗
59. 10.1021/ja016812s10.1021/ja016812s ↗
60. 10.1002/adma.20190653910.1002/adma.201906539 ↗
61. 10.1007/s13139-020-00635-w10.1007/s13139-020-00635-w ↗
62. 10.1016/j.cbpa.2018.04.01410.1016/j.cbpa.2018.04.014 ↗
63. 10.1088/1361-6560/aab13610.1088/1361-6560/aab136 ↗
64. 10.1016/j.jmmm.2018.09.11410.1016/j.jmmm.2018.09.114 ↗
65. 10.1088/1361-6560/aacb8710.1088/1361-6560/aacb87 ↗
66. 10.1016/j.molonc.2008.04.00110.1016/j.molonc.2008.04.001 ↗
67. 10.1200/JCO.2007.14.306510.1200/JCO.2007.14.3065 ↗
68. 10.1021/acsnano.7b0578410.1021/acsnano.7b05784 ↗
69. 10.1021/acs.nanolett.6b0486510.1021/acs.nanolett.6b04865 ↗
70. 10.14326/abe.3.3710.14326/abe.3.37 ↗
71. 10.1088/0031-9155/54/5/L0110.1088/0031-9155/54/5/L01 ↗
72. 10.7150/thno.1372810.7150/thno.13728 ↗
73. 10.1021/acsnano.8b0089310.1021/acsnano.8b00893 ↗
74. 10.1038/nature0380810.1038/nature03808 ↗
75. 10.1109/TMI.2016.254204110.1109/TMI.2016.2542041 ↗
76. Vivotrax. https://www.magneticinsight.com/store/mivt01-5-vials/ (accessed 2020-11-14).
77. 10.1118/1.355464610.1118/1.3554646 ↗
78. 10.1021/acs.nanolett.7b0382910.1021/acs.nanolett.7b03829 ↗
79. 10.1039/C6NR08468K10.1039/C6NR08468K ↗
80. 10.1021/ac200550d10.1021/ac200550d ↗
81. 10.1016/j.biomaterials.2011.08.07610.1016/j.biomaterials.2011.08.076 ↗
82. 10.1021/nn403281e10.1021/nn403281e ↗
83. 10.1016/j.exphem.2009.06.00310.1016/j.exphem.2009.06.003 ↗
84. 10.1002/btpr.10110.1002/btpr.101 ↗
85. 10.1021/acsami.6b0326210.1021/acsami.6b03262 ↗
86. 10.1021/acsnano.5b0024010.1021/acsnano.5b00240 ↗
87. 10.1021/acs.analchem.5b0332010.1021/acs.analchem.5b03320 ↗
88. 10.1021/am505041a10.1021/am505041a ↗
89. 10.1021/acs.analchem.8b0133010.1021/acs.analchem.8b01330 ↗
90. 10.1088/0034-4885/78/1/01660110.1088/0034-4885/78/1/016601 ↗
91. 10.1038/255706a010.1038/255706a0 ↗
92. 10.1038/268437a010.1038/268437a0 ↗
93. 10.1002/cyto.99011020310.1002/cyto.990110203 ↗
94. 10.1053/j.seminoncol.2016.06.00410.1053/j.seminoncol.2016.06.004 ↗
95. FDA Approves CliniMACS CD34 Reagent System for the Prevention of Graft-vs-Host Disease in AML. https://www.ascopost.com/issues/february-15-2014/fda-approves-clinimacs-cd34-reagent-system-for-the-prevention-of-graft-vs-host-disease-in-aml/ (accessed 2020-11-14).
96. CELLSEARCH Circulating Tumor Cell Kit. https://www.cellsearchctc.com/product-systems-overview/cellsearch-ctc-kit (accessed 2021-11-04).
97. CliniMACS CD34 Product Line. https://www.miltenyibiotec.com/US-en/products/clinimacs-cd34-product-line.html#gref (accessed 2021-11-04).
98. 10.3389/fphar.2018.0083110.3389/fphar.2018.00831 ↗
99. 10.1021/acsami.8b0239810.1021/acsami.8b02398 ↗
100. 10.1097/00000658-195710000-0000710.1097/00000658-195710000-00007 ↗